According to the notice issued by the Drugs Controller General of India (DCGI), Dr Rajeev Raghuvanshi, "Mis Novo Nordisk has informed about a theft of its products, as mentioned below, during transit ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

Certain batches of injectable medicines, including insulin and weight-loss drugs, were reported stolen in transit. Experts ...

This is but a fact that obesity drugs are only going to get more accessible for Indians post-March 2026. But whether they ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...